Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 4/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 4/20 | 0.31 |
| ▸ | BCR | P11274 | 4/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775869 | 0.84 | TRPV1 (0.42) | RPS6KA3ABL1BCRKIT | |
| SCHEMBL16776099 | 0.83 | FGFR4 (0.40) | WDR5RPS6KA3PDE4BFAAHRPS6KA2 | |
| SCHEMBL16775828 | 0.82 | PIKFYVE (0.37) | KIT | |
| SCHEMBL16776100 | 0.82 | FGFR4 (0.42) | — | |
| SCHEMBL16776098 | 0.81 | FGFR4 (0.43) | WDR5FAAHMTORRPS6KA2 | |
| SCHEMBL16775840 | 0.80 | PIKFYVE (0.37) | KIT | |
| SCHEMBL19365693 | 0.79 | TRPV1 (0.34) | PRMT3 | |
| SCHEMBL16776157 | 0.76 | ROCK2 (0.36) | PRMT3ABL1BCRRPS6KA2 | |
| SCHEMBL16775881 | 0.76 | TRPV1 (0.43) | RPS6KA3 | |
| SCHEMBL16775870 | 0.75 | GRM5 (0.39) | RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | WDR5 403/4885RPS6KA3 2368/4885PDE4B 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.